Key result
Application of the 2014 SCD risk model identified only 20% of HCM patients as candidates for ICD therapy, compared to up to 85% using the 2003 model.
Why the study?
Does the 2014 European SCD risk model differ from the 2003 model in estimating SCD risk and ICD indications in patients with hypertrophic cardiomyopathy?
Observational (n=103)
Does the 2014 European SCD risk model differ from the 2003 model in estimating SCD risk and ICD indications in patients with hypertrophic cardiomyopathy?
The 2014 European SCD risk model for hypertrophic cardiomyopathy significantly reduces the proportion of patients considered candidates for primary prevention ICD therapy compared to the older 2003 model.
Answers are grounded in this paper and cite their sources.
May reduce ICD candidates in HCM; leaves open prospective validation of SCD outcomes versus the 2003 model.
Objective Hypertrophic cardiomyopathy (HCM) is associated with a risk of sudden cardiac death (SCD). Several models have been developed to estimate SCD risk and guide preventive therapy. The comparison of the previous 2003 with novel 2014 SCD risk models have never been studied. Methods Over a year we included 103 consecutive HCM patients without previous cardiac arrest and/or ICD implanted (65% males; aged 53.3 ± 13.9 years; mean EF 62.3 ± 18%). The SCD risk was calculated for each patient. Results Based on the 2003 model, patients had following scores: 0 points -15 (15%) patients, 1-28 (27%), 2-34 (33%), 3-18 (17%), ≥ 4-8 (8%). According to the 2014 model 83 (80%) had low risk, 12 (12%) intermediate risk, and only 8 (8%) high risk. Patients who had an intermediate or high risk in the 2003 model but a low risk in 2014 model were the oldest, experienced less frequently syncope and nsVT, but had more often abnormal blood pressure response to exercise and an intermediate LVOT gradient in comparison to the patients who had consistently low or high risk in both models. Conclusions Calculation of SCD risk using two models provides completely different risk estimates and consequently different guidance on SCD primary prevention. According to the 2003 model up to 85% of patients have indications for ICD, whereas based on the 2014 risk model only 20% of the patients had non-negligible SCD risk and are candidates for ICD therapy. SCD risk markers, used in the 2003 and 2014 models, have various discriminating power.
No takes yet. Share an insight, caveat, or question.
Rubiś et al. (2017) conducted an observational in Hypertrophic cardiomyopathy (HCM) (n=103). 2014 SCD risk model vs. 2003 SCD risk model was evaluated on Proportion of patients with indications for ICD therapy. Application of the 2014 SCD risk model identified only 20% of HCM patients as candidates for ICD therapy, compared to up to 85% using the 2003 model.
Synapse has enriched 10 related papers. Consider them for comparative context: